Article
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.
Lancet (London, England) - 30 Oct 2010
Ong Kim-Thanh, Perdu Jérôme, De Backer Julie, Bozec Erwan, Collignon Patrick, Emmerich Joseph, Fauret Anne-Laure, Fiessinger Jean-Noël, Germain Dominique P, Georgesco Gabriella, Hulot Jean-Sebastien, De Paepe Anne, Plauchu Henri, Jeunemaitre Xavier, Laurent Stéphane, Boutouyrie Pierre
Abstract excerpt
BACKGROUND: Vascular Ehlers-Danlos syndrome is a rare severe disease that causes arterial dissections and ruptures that can lead to early death. No preventive treatment has yet been validated. Our aim was to assess the ability of celiprolol, a β(1)-adrenoceptor antagonist with a β(2)-adrenoceptor agonist action, to prevent arterial dissections and ruptures in vascular Ehlers-Danlos syndrome. METHODS: Our study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.